dornase


Also found in: Dictionary, Wikipedia.

dor·nase

(dōr'nās),
Obsolete contraction of deoxyribonuclease.
See also: streptodornase.

dornase

(1) Deoxyribonuclease I, EC 3.1.21.1.
(2) Deoxy-ribonuclease II, EC 3.1.22.1.

dornase

(dor′nās)
Short for deoxyribonuclease.

dornase alfa

An enzyme that lessens the viscosity of sputum by cleaving DNA deposited in it. It is used to treat patients with cystic fibrosis, who have exceptionally thick pulmonary secretions that are hard to expectorate.

pancreatic dornase

Dornase prepared from beef pancreas, used to loosen thick pulmonary secretions.

dornase

a shortened term for deoxyribonuclease; also a word termination, as in streptodornase.
References in periodicals archive ?
Hence, the importance of dornase alfa's mode of mechanism of breaking down extracellular DNA to decrease the viscosity of mucus.
Dornase alfa is administered through inhalation, during which minimal systemic absorption occurs.
Dornase Alfa - Dornase alfa reduces extracellular DNA and binding polymers to reduce viscosity.
6 years old, the mean lung function at baseline was 92% of the predicted normal value of FEV1, and the use of concomitant medications included inhaled antibiotics (37%), dornase alfa (Pulmozyme([R])) (77%) and oral macrolide antibiotics (40%).
Auric 10 Combination Neomicinum + Bacitracinum 11 Combination Oximed 12 Diclofenacum 50 Mg Miscellaneous 13 Liv 52 14 Dobutaminum 15 Dornase Alfa 1Mg Ml 16 Epinephrinum 1 Mg 1 Ml 17 Ertapenemum 18 Esomeprazolum Nij.
Pulmoxen, for the treatment of cystic fibrosis: Pre-clinical research has been completed and a unique high-production eukaryotic strain was created for the producer of a fused protein dornase alfa.
Food and Drug Administration (FDA), including dornase alfa, tobramycin, macrolides and digestive enzymes, will be permitted in the trial.
8 sgb v into finished products containing the active ingredient dornase alfa.
To ensure that results from this trial are predictive of efficacy in heavily treated cystic fibrosis patient and consistent with current clinical practice, the study will enroll patients that have recently received multiple courses of inhaled antibiotics and in most cases are receiving concomitant medication such as dornase alpha, azithromycin and hypertonic saline.
dornase alfa, high-dose ibuprofen and pancreatic enzyme), FEV(1) % predicted, and use of medical resources.
To ensure that results from this trial were as predictive as possible for the future Phase 3 program and consistent with current clinical practice, the study enrolled patients that had recently received multiple courses of inhaled antibiotics and in most cases were receiving concomitant medication such as dornase alpha, azithromycin and hypertonic saline that have been shown in previous studies to improve lung function and/or reduce exacerbations.
The key secondary endpoint of the trial was to assess whether Bronchitol further improves lung function in patients already being treated with the most commonly used CF therapeutic, dornase alfa (Pulmozyme(TM)).